JAMES L. TULLIS, M.D., F.A.C.P.
It has been known for more than 50 years that heterologous platelet antibodies can induce experimental thrombocytopenic purpura1-3 and that iso-immune leukocyte antibodies can lead to pyrogenic and urticarial transfusion reactions.4 Yet surprisingly little attempt was made to transfer these concepts to clinical states of leukopenia and thrombocytopenia until Oliva and Burbetta5 in 1944 and Evans et al.6 in 1948 showed in vitro evidence of cytotoxic substances in plasma, and Harrington et al.7 shortly thereafter found profound in vivo thrombocytopenic activity of plasma from a patient with idiopathic thrombocytopenic purpura.
These latter studies were soon followed by the development of
JAMES L. TULLIS. THE ROLE OF LEUKOCYTE AND PLATELET ANTIBODY TESTS IN MANAGEMENT OF DIVERSE CLINICAL DISORDERS(THE ROLE OF LEUKOCYTE AND PLATELET ANTIBODY TESTS IN MANAGEMENT OF DIVERSE CLINICAL DISORDERS*†)(THE ROLE OF LEUKOCYTE AND PLATELET ANTIBODY TESTS IN MANAGEMENT OF DIVERSE CLINICAL DISORDERS*†). Ann Intern Med. 1961;54:1165–1180. doi: 10.7326/0003-4819-54-6-1165
Download citation file:
Published: Ann Intern Med. 1961;54(6):1165-1180.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use